Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

by Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret
Published 2021-08-01

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

by John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, Steve Songer, C. L. Beach, Hervé Dombret
Published 2017-12-01